Johnson & Johnson (NYSE:JNJ) Shares Acquired by Clarkston Capital Partners LLC

Clarkston Capital Partners LLC lifted its stake in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 9.9% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 114,927 shares of the company’s stock after purchasing an additional 10,341 shares during the quarter. Clarkston Capital Partners LLC’s holdings in Johnson & Johnson were worth $20,401,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. RE Dickinson Investment Advisors LLC grew its stake in shares of Johnson & Johnson by 163.3% during the 1st quarter. RE Dickinson Investment Advisors LLC now owns 158 shares of the company’s stock worth $28,000 after purchasing an additional 98 shares during the period. Advanced Research Investment Solutions LLC grew its stake in shares of Johnson & Johnson by 200.0% during the 1st quarter. Advanced Research Investment Solutions LLC now owns 180 shares of the company’s stock worth $32,000 after purchasing an additional 120 shares during the period. Morton Brown Family Wealth LLC grew its stake in shares of Johnson & Johnson by 78.0% during the 2nd quarter. Morton Brown Family Wealth LLC now owns 178 shares of the company’s stock worth $32,000 after purchasing an additional 78 shares during the period. Professional Financial Advisors LLC boosted its position in shares of Johnson & Johnson by 47.9% in the 1st quarter. Professional Financial Advisors LLC now owns 210 shares of the company’s stock worth $37,000 after buying an additional 68 shares in the last quarter. Finally, Goodman Advisory Group LLC purchased a new stake in shares of Johnson & Johnson in the 2nd quarter worth about $39,000. 68.59% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Trading Up 0.8 %

NYSE JNJ opened at $176.20 on Monday. Johnson & Johnson has a 12 month low of $155.72 and a 12 month high of $186.69. The company has a 50-day moving average of $167.84 and a 200-day moving average of $171.29. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.43 and a quick ratio of 1.18. The company has a market cap of $460.67 billion, a P/E ratio of 24.54, a P/E/G ratio of 3.49 and a beta of 0.57.

Johnson & Johnson (NYSE:JNJGet Rating) last posted its quarterly earnings data on Tuesday, October 18th. The company reported $2.55 EPS for the quarter, beating analysts’ consensus estimates of $2.49 by $0.06. Johnson & Johnson had a net margin of 19.95% and a return on equity of 35.37%. The company had revenue of $23.79 billion during the quarter, compared to the consensus estimate of $23.44 billion. During the same quarter in the prior year, the company posted $2.60 EPS. The company’s quarterly revenue was up 1.9% compared to the same quarter last year. As a group, equities analysts predict that Johnson & Johnson will post 10.04 earnings per share for the current year.

Johnson & Johnson announced that its Board of Directors has initiated a stock buyback plan on Wednesday, September 14th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the company to reacquire up to 1.2% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company’s leadership believes its shares are undervalued.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 6th. Investors of record on Tuesday, November 22nd will be given a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a yield of 2.57%. The ex-dividend date is Monday, November 21st. Johnson & Johnson’s dividend payout ratio (DPR) is presently 62.95%.

Insider Buying and Selling

In related news, EVP Kathryn E. Wengel sold 16,410 shares of the stock in a transaction that occurred on Wednesday, November 9th. The shares were sold at an average price of $173.42, for a total transaction of $2,845,822.20. Following the completion of the sale, the executive vice president now owns 71,311 shares of the company’s stock, valued at approximately $12,366,753.62. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Johnson & Johnson news, VP Thibaut Mongon sold 35,246 shares of the stock in a transaction that occurred on Friday, November 4th. The shares were sold at an average price of $171.18, for a total value of $6,033,410.28. Following the completion of the sale, the vice president now owns 40,133 shares of the company’s stock, valued at $6,869,966.94. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Kathryn E. Wengel sold 16,410 shares of the stock in a transaction that occurred on Wednesday, November 9th. The shares were sold at an average price of $173.42, for a total transaction of $2,845,822.20. Following the completion of the sale, the executive vice president now directly owns 71,311 shares of the company’s stock, valued at approximately $12,366,753.62. The disclosure for this sale can be found here. In the last quarter, insiders sold 118,795 shares of company stock valued at $20,230,174. 0.35% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on JNJ shares. Credit Suisse Group started coverage on shares of Johnson & Johnson in a research report on Thursday. They issued a “neutral” rating and a $170.00 price objective on the stock. StockNews.com started coverage on shares of Johnson & Johnson in a research report on Wednesday, October 12th. They issued a “strong-buy” rating on the stock. Bank of America decreased their price objective on shares of Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating on the stock in a research report on Friday, October 14th. Morgan Stanley decreased their price objective on shares of Johnson & Johnson from $174.00 to $170.00 and set an “equal weight” rating on the stock in a research report on Wednesday, October 19th. Finally, Barclays assumed coverage on shares of Johnson & Johnson in a report on Monday, October 17th. They issued an “equal weight” rating and a $175.00 target price on the stock. Seven investment analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $181.33.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Articles

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.